Botanix Pharmaceuticals Limited (BXPHF)
USD 0.23
(0.0%)
USD 0.23
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 | -13.86 Million AUD | -51.52% |
| 2023 | -9.15 Million AUD | 30.5% |
| 2022 | -13.17 Million AUD | -295.04% |
| 2021 | -3.33 Million AUD | 80.07% |
| 2020 | -16.73 Million AUD | 1.81% |
| 2019 | -17.03 Million AUD | -54.74% |
| 2018 | -11.01 Million AUD | -130.71% |
| 2017 | -4.77 Million AUD | -179.39% |
| 2016 | -1.7 Million AUD | -68.39% |
| 2015 | -1.01 Million AUD | 10.3% |
| 2014 | -1.13 Million AUD | 38.75% |
| 2013 | -1.84 Million AUD | -17.76% |
| 2012 | -1.56 Million AUD | -3.18% |
| 2011 | -1.51 Million AUD | 23.58% |
| 2010 | -1.98 Million AUD | 34.66% |
| 2009 | -3.04 Million AUD | -7.72% |
| 2008 | -2.82 Million AUD | 17.32% |
| 2007 | -3.41 Million AUD | -22.08% |
| 2006 | -2.79 Million AUD | -133506.86% |
| 2005 | 2098.00 AUD | 100.22% |
| 2004 | -958 Thousand AUD | 31.52% |
| 2003 | -1.39 Million AUD | 0.78% |
| 2002 | -1.41 Million AUD | -299.43% |
| 2001 | -353 Thousand AUD | 88.87% |
| 2000 | -3.17 Million AUD | -3631.76% |
| 1999 | -85 Thousand AUD | -200.0% |
| 1998 | 85 Thousand AUD | -35.61% |
| 1997 | 132 Thousand AUD | 0.0% |
| 1996 | - AUD | 100.0% |
| 1995 | -234 Thousand AUD | 83.61% |
| 1994 | -1.42 Million AUD | -58.84% |
| 1993 | -899 Thousand AUD | 0.0% |
| 1992 | - AUD | 100.0% |
| 1991 | -61 Thousand AUD | 31.46% |
| 1990 | -89 Thousand AUD | -23.61% |
| 1989 | -72 Thousand AUD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q3 | -4.2 Million AUD | 23.15% |
| 2024 Q1 | -2.73 Million AUD | 40.01% |
| 2024 FY | -13.86 Million AUD | -51.52% |
| 2024 Q2 | -5.46 Million AUD | -100.0% |
| 2024 Q4 | -4.2 Million AUD | 0.0% |
| 2023 FY | -9.15 Million AUD | 30.5% |
| 2023 Q2 | -4.59 Million AUD | -100.0% |
| 2023 Q3 | -2.27 Million AUD | 50.44% |
| 2023 Q1 | -2.29 Million AUD | 65.5% |
| 2023 Q4 | -4.55 Million AUD | -100.0% |
| 2022 Q1 | -3.25 Million AUD | 18.6% |
| 2022 Q3 | -3.33 Million AUD | 48.82% |
| 2022 Q4 | -6.66 Million AUD | -100.0% |
| 2022 Q2 | -6.5 Million AUD | -100.0% |
| 2022 FY | -13.17 Million AUD | -295.04% |
| 2021 Q4 | -3.99 Million AUD | -100.0% |
| 2021 FY | -3.33 Million AUD | 80.07% |
| 2021 Q1 | 332.06 Thousand AUD | 103.41% |
| 2021 Q2 | 664.12 Thousand AUD | 100.0% |
| 2021 Q3 | -1.99 Million AUD | -401.01% |
| 2020 Q1 | -3.49 Million AUD | 72.8% |
| 2020 Q3 | -4.86 Million AUD | 30.42% |
| 2020 Q2 | -6.99 Million AUD | -100.0% |
| 2020 FY | -16.73 Million AUD | 1.81% |
| 2020 Q4 | -9.73 Million AUD | -100.0% |
| 2019 FY | -17.03 Million AUD | -54.74% |
| 2019 Q1 | -2.09 Million AUD | 51.49% |
| 2019 Q2 | -2.09 Million AUD | 0.0% |
| 2019 Q3 | -6.42 Million AUD | -207.53% |
| 2019 Q4 | -12.85 Million AUD | -100.0% |
| 2018 Q4 | -4.3 Million AUD | 0.0% |
| 2018 Q3 | -4.3 Million AUD | -260.29% |
| 2018 Q2 | -1.19 Million AUD | 0.0% |
| 2018 FY | -11.01 Million AUD | -130.71% |
| 2018 Q1 | -1.19 Million AUD | 32.17% |
| 2017 Q2 | -623 Thousand AUD | 0.0% |
| 2017 FY | -4.77 Million AUD | -179.39% |
| 2017 Q4 | -1.76 Million AUD | 0.0% |
| 2017 Q1 | -623 Thousand AUD | 0.0% |
| 2017 Q3 | -1.76 Million AUD | -183.07% |
| 2016 FY | -1.7 Million AUD | -68.39% |
| 2015 FY | -1.01 Million AUD | 10.3% |
| 2014 FY | -1.13 Million AUD | 38.75% |
| 2013 FY | -1.84 Million AUD | -17.76% |
| 2012 FY | -1.56 Million AUD | -3.18% |
| 2011 FY | -1.51 Million AUD | 23.58% |
| 2010 FY | -1.98 Million AUD | 34.66% |
| 2009 FY | -3.04 Million AUD | -7.72% |
| 2008 FY | -2.82 Million AUD | 17.32% |
| 2007 FY | -3.41 Million AUD | -22.08% |
| 2006 FY | -2.79 Million AUD | -133506.86% |
| 2005 FY | 2098.00 AUD | 100.22% |
| 2004 FY | -958 Thousand AUD | 31.52% |
| 2003 FY | -1.39 Million AUD | 0.78% |
| 2002 FY | -1.41 Million AUD | -299.43% |
| 2001 FY | -353 Thousand AUD | 88.87% |
| 2000 FY | -3.17 Million AUD | -3631.76% |
| 1999 FY | -85 Thousand AUD | -200.0% |
| 1998 FY | 85 Thousand AUD | -35.61% |
| 1997 FY | 132 Thousand AUD | 0.0% |
| 1996 FY | - AUD | 100.0% |
| 1995 FY | -234 Thousand AUD | 83.61% |
| 1994 FY | -1.42 Million AUD | -58.84% |
| 1993 FY | -899 Thousand AUD | 0.0% |
| 1992 FY | - AUD | 100.0% |
| 1991 FY | -61 Thousand AUD | 31.46% |
| 1990 FY | -89 Thousand AUD | -23.61% |
| 1989 FY | -72 Thousand AUD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Bioxytran, Inc. | -4.28 Million USD | -224.058% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 81.498% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -4973.009% |
| SQZ Biotechnologies Company | -79.46 Million USD | 82.546% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | -379.524% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 126.18% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 121.294% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -661.851% |
| Marizyme, Inc. | -65.34 Million USD | 78.775% |
| Genus plc | 7.9 Million USD | 275.566% |
| Pharming Group N.V. | -10.54 Million USD | -31.491% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | -539.212% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | -273.823% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | -56.826% |
| ContraFect Corporation | -65.15 Million USD | 78.712% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -702.898% |
| IMV Inc. | -36.48 Million USD | 61.986% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | -72.088% |
| ONE Bio Corp. | 8.67 Million USD | 259.852% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 73.169% |
| Mesoblast Limited | -87.95 Million USD | 84.231% |
| MultiCell Technologies, Inc. | -380.07 USD | -3649151.191% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | -271.543% |
| Genscript Biotech Corporation | -95.47 Million USD | 85.473% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -2093.162% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | -482.548% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | -110.911% |
| Biomind Labs Inc. | -1.21 Million USD | -1042.18% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | -347.155% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | -75.497% |
| Skye Bioscience, Inc. | -37.64 Million USD | 63.156% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -611.541% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | -27.342% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -92512.907% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | -183.863% |
| Arch Therapeutics, Inc. | -6.98 Million USD | -98.626% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 12.612% |
| Accustem Sciences Inc. | -3.74 Million USD | -270.212% |
| EV Biologics, Inc. | -1.26 Million USD | -994.573% |
| Q BioMed Inc. | -2.05 Million USD | -575.881% |
| GB Sciences, Inc. | -1.36 Million USD | -918.576% |
| Alpha Cognition Inc. | -13.77 Million USD | -0.705% |
| CSL Limited | 2.64 Billion USD | 100.525% |
| Agentix Corp. | -1.37 Million USD | -909.285% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 76.778% |
| Enzolytics Inc. | -2.17 Million USD | -537.151% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Resverlogix Corp. | -3.61 Million USD | -284.202% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | -337.332% |
| MetaStat, Inc. | - USD | Infinity% |
| Curative Biotechnology, Inc. | -5.81 Million USD | -138.424% |
| argenx SE | -295.05 Million USD | 95.299% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 77.844% |
| HST Global, Inc. | -146.21 Thousand USD | -9386.156% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 14252.764% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -690.4% |
| Halberd Corporation | -79.67 Thousand USD | -17307.637% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 300.296% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | -358.331% |
| Zenith Capital Corp. | -10.59 Million USD | -30.896% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | -249.1% |
| GeneThera, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | -234.537% |
| AVAX Technologies, Inc. | -6.41 Million USD | -116.253% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -22847.665% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -591.716% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -59575.196% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Adynxx, Inc. | - USD | Infinity% |
| NovAccess Global Inc. | -4.76 Million USD | -190.819% |
| Helix BioMedix, Inc. | -1.05 Million USD | -1213.349% |
| Capstone Therapeutics Corp. | -3.81 Million USD | -263.176% |
| Kadimastem Ltd | -3.3 Million USD | -319.354% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| BioStem Technologies, Inc. | -8.48 Million USD | -63.5% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -3042.429% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -938.594% |
| LadRx Corporation | 400.44 Thousand USD | 3563.591% |
| Cell Source, Inc. | -5.32 Million USD | -160.649% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -3238.245% |
| Regen BioPharma, Inc. | 1.02 Million USD | 1455.115% |
| Regen BioPharma, Inc. | 1.02 Million USD | 1455.115% |
| Affymax, Inc. | -14.42 Million USD | 3.843% |
| Mobile Lads Corp. | -2.26 Million USD | -512.811% |
| Itoco Inc. | -1.86 Million USD | -642.094% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | -212.203% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -731.019% |
| International Stem Cell Corporation | -131 Thousand USD | -10487.564% |
| CytoDyn Inc. | -49.84 Million USD | 72.172% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -17449.263% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -5979.819% |
| Qrons Inc. | -789.34 Thousand USD | -1657.112% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -1373.105% |
| SYBLEU INC | -180.3 Thousand USD | -7592.402% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -2.08 Million USD | -564.359% |
| Rebus Holdings, Inc. | -1.02 Million USD | -1259.775% |
| GlobeImmune, Inc. | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -760.011% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -25455.92% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | -448.156% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 71.148% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | -556.088% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -1676.148% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | -337.806% |
| Neutra Corp. | -233.46 Thousand USD | -5840.809% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 31.646% |
| PureTech Health plc | -65.69 Million USD | 78.888% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 34.782% |
| IXICO plc | -1.17 Million USD | -1077.395% |
| IntelGenx Technologies Corp. | -9.92 Million USD | -39.717% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 75.722% |
| CSL Limited | 2.64 Billion USD | 100.525% |
| Cellectis S.A. | -103.17 Million USD | 86.557% |